硫培南
| 中文名称 | 硫培南 |
|---|---|
| 中文同义词 | 硫陪南;硫培南;CP-70,429; CP 70,429; CP70,429; CP-70429; CP 70429; CP70429; SULOPENEM;舒仑培南;(5R,6S)-6-((R)-1-羟乙基)-3-(((1R,3S)-1-氧化氢化噻吩-3-基)硫代)-7-氧代-4-噻-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸 |
| 英文名称 | Sulopenem |
| 英文同义词 | (S)-3-[[(5R)-2-Carboxy-6β-[(R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]tetrahydrothiophene 1-oxide;CP-65207-S;CP-70429;Sulopenem;(5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-, (5R,6S)-;Sulopenem USP/EP/BP;(5R,6S)-6-((R)-1-hydroxyethyl)-3-(((1R)-1-oxidotetrahydrothiophen-3-yl)thio)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| CAS号 | 120788-07-0 |
| 分子式 | C12H15NO5S3 |
| 分子量 | 349.45 |
| EINECS号 | 604-604-1 |
| 相关类别 | 医药原料;API |
| Mol文件 | 120788-07-0.mol |
| 结构式 |  |
硫培南 性质
| 沸点 | 693.1±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.74±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.88±0.40(Predicted) |
| 颜色 | 白色至黄色 |
| InChI | InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1 |
| InChIKey | FLSUCZWOEMTFAQ-PRBGKLEPSA-N |
| SMILES | N12[C@@]([H])([C@@H]([C@H](O)C)C1=O)SC(S[C@H]1CC[S@@](=O)C1)=C2C(O)=O |
硫培南是一种具有口服活性的肠胃外青霉烯类抗生素，对革兰氏阳性菌和革兰氏阴性菌具有广谱活性。它可用于尿路感染和腹腔内感染的研究，它对铜绿假单胞菌和嗜黄单胞菌的嗜麦芽孢杆菌无效。
MIC: 0.015-0.12 µg/mL ( E. coli )
Sulopenem has the potential for uncomplicated and complicated urinary tract infections and intra-abdominal infections treatment, including multidrug-resistant (MDR) infections and infections attributable to quinolone-nonsusceptible and/or extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli.
Sulopenem inhibits the growth of most isolates of aerobic and anaerobic Gram-positive and Gram-negative bacteria, including methicillin-susceptible
Staphylococcus aureus
,
Streptococcus pneumoniae
(penicillin-susceptible and -resistant isolates), group A and B β-hemolytic streptococci,
Listeria monocytogenes
,
Enterobacteriaceae
,
Haemophilus influenzae
, and
Moraxella catarrhalis
but excluding
P. aeruginosa
and
Stenotrophomonas maltophilia
, at a concentration of ≤1 μg/mL.
The protective effects of Sulopenem in murine experimental systemic infections are superior to those of Imipenem/Cilastatin. In murine experimental mixed infection with Escherichia coli and Bacteroides fragilis , Sulopenem has lower ED 50 . In guinea pigs experimental lung infection with Klebsiella pneumoniae , Sulopenem is more effective than CZON or Cefotiam.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-105284 | 硫培南 Sulopenem | 120788-07-0 | 1 mg | 1818元 |
| 2025/12/22 | HY-105284 | 硫培南 Sulopenem | 120788-07-0 | 5mg | 4000元 |